3SOF

Scolr Pharma, Inc. Formerly known as Scolr, Inc.. The Group principal activity is to manufacture nutraceutical-based health and dietary supplements for the animal and human nutrition markets. The Group also provides a biopharmaceutical leverage specialized knowledge, proprietary & patented products and technologies, such as the patented CDT. The CDT platform currently consists of three patented drug delivery technologies for prescription drugs, over-the-counter (OTC) products & nutraceuticals. The Group's CDT technology is designed to produce tablets or capsules that release their active agents predictably & programmably over a specified timeframe of up to 24 hours. The technology has been used to develop dietary supplement products that are being manufactured & distributed by third parties. Its CDT Glucosamine and Chondroitin product is available nationwide in more than 8,000 retail outlets, including Wal-Mart (under the Spring Valley label), Trader Joe's (under the Trader Darwin's label) and Rite Aid stores.

Price actin broke out of a nice symetrical triangle on heavy volume which gives us a technical price target of 5.14.

Heres the news that broke price asction out of the triangle on the 21st.

   SCOLR Pharma and Perrigo Announce Strategic Alliance to Manufacture and Market CDT(R) Nutritional Productshttp://biz.yahoo.com/prnews/051020/deth036.html?.v=15

-fousc

Nothing to exciting with today's price action, though price action was able to close above the prior spike high of 4.50 but only by a penny on about average volume. This one has the ability to be volitile, lets see if it can do it again.

-fousc

Price action breakout from recent resistence at 4.50, gap up on increased volume and news.

SCOLR Pharma to Present at American Association of Pharmaceutical Scientists - AAPS - Annual Meeting and Exposition
11/2/2005 9:05:01 AM

   BELLEVUE, Wash., Nov 02, 2005 (BUSINESS WIRE) -- SCOLR Pharma, Inc. (DDD) announced today that representatives from its research and development team will be presenting a total of four CDT(R) drug delivery research papers at the 2005 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting to be held November 6-10, 2005 in Nashville, TN.

SCOLR Pharma will make the following four poster presentations at the convention:

-- 1. "In Vivo-In Vitro Correlation of a 120mg Pseudoephedrine Hydrochloride Extended Release Monolithic Tablet and Bioequivalence to Reference-Listed Product" (Tennessee Ballroom Poster M1261 available Monday, November 7th, 1:00 p.m. - 5:00 p.m.)

-- 2. "In Vivo-In Vitro Correlation of a 600mg Monolithic, High-Speed Manufacturable Controlled-Release Ibuprofen Tablet" (Tennessee Ballroom Poster W4106 available Wednesday, November 9th, 8:00 a.m. - 12:00 p.m.)

-- 3. "Investigation of In Vitro Dissolution Methods for Extended Release Ibuprofen Tablets and Correlation to In Vivo BA/BE Studies" (Tennessee Ballroom Poster W4315 available Wednesday, November 9th, 8:00 a.m. - 12:00 p.m.)

-- 4. "Compatibility Studies for a Novel Ibuprofen Controlled-Release Tablet" (Tennessee Ballroom Poster R6005 available Thursday, November 10th, 8:00 a.m. - 12:00 p.m.)

SCOLR Pharma will engage the pharmaceutical scientific community with discussions of its patented, advanced oral drug delivery technologies and to address questions related to its presentations. SCOLR Pharma will be exhibiting at the AAPS show in booth #3106.

Based in Bellevue, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company leveraging formulation expertise and its patented CDT platform to introduce distinctive and novel OTC products, prescription drugs and dietary supplements. SCOLR Pharma's CDT drug delivery platform provides distinctive products with tangible benefits for the consumer and competitive commercial advantages for licensees. For more information on SCOLR Pharma, please call 425-373-0171 or visit http://www.scolr.com/.

For more information on AAPS and its Annual Meeting and Exposition in Nashville, TN, please visit http://www.aapspharmaceutica.com.


-fousc

increased volume today though it looks like bulls are having some trouble breaking away from this resistence zone. We'll see what fortune fridays will bring us 

-fousc

DDD had a nice breakout today to new highs above the prior peak high in july of 4.65 on above average volume. Could see higher prices to come.

-fousc

Howdie FOUSC
Do you feel that this is a run up into earnings?  They dropped after last poor earnings?  PAX looks interesting.  Your persistance on this thread is admirable, .18 up today, you feel that it still has potential?  when do earnings come out?
do not forget your noodles  NWD
and i have it on a good source that ZENX should see a rise of $.20 or so in the near future
cheers
Joe

Hey joe,

Im not sure if this is a run up to earnings, i really have no idea what there current financial situation is, This is a technical play for me. All i know is that the general trend is bullish. I looked for a release date for Q3 earnings but wasn't listed on marketwatch.com or yahoo finance. And the Q2 earnings you mentioned were everything but good, Q2 rev $110,852 vs $211,143 of 2004, had little effect on the stock price. There was a 4 day retracement after the release on 8/12/05 and as been headin north ever since. Recent volume has been fairly heavy and today broke out of a resistence zone. So yes, i do there could be higher pps in the near future.

-fousc

DDD... Again made a 52 week high.... volume increasing significantly
-----Still looks good for entry

Recent News has triggered a,
bottom reversal based on the NDA forecast that's filling recent downgap.


52wk Range: 1.51 - 6.10
Volume: 277,600
Avg Vol (3m): 133,295

Technicals
Percentage Gainer

Last Price Quote is:
19.23%above 13-day EMA
-3.40%below 50-day EMA
RS Rating: 3 

Fundamentals
Key Data:
Market Cap (M): $129.94 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: N/A

REPORTS EXTENSION OF RESEARCH AGREEMENT: SCOLR Pharma, Inc. (DDD) announced
an extension of its research agreement with a global consumer products company to
co-develop a novel application of its CDT(R) drug delivery technology. Under the terms of the
agreement, SCOLR will receive a research fee. If the program is successful, it is anticipated that
the parties would enter a global license agreement to allow for application of SCOLR's technology.